论文部分内容阅读
目的:探讨~(131)I对男性甲状腺功能亢进症患者血清性激素及甲状腺球蛋白水平的影响。方法:收集我院收治的男性甲状腺功能亢进症患者74例,随机分为对照组和实验组,每组各37例,对照组患者给予他巴唑口服,20-30 mg/次,每日口服1次。实验组患者在对照组基础上给予~(131)I治疗。治疗结束后,检测并比较两组患者血清游离三碘甲状腺素(FT3)、游离甲状腺素(FT4)、促甲状腺激素(TSH)、睾酮(T)、雌二醇(E2)、甲状腺球蛋白(TG)水平的变化以及临床疗效。结果:与治疗前相比,两组患者血清FT3、FT4、T、E2、TG水平均显著下降,TSH水平明显升高(P<0.05);与对照组相比,实验组患者血清FT3、FT4、T、E2、TG水平较低,TSH水平以及临床治疗有效率较高(P<0.05)。结论:~(131)I能够显著降低男性甲状腺功能亢进症血清FT3、FT4、T、E2、TG水平,升高TSH水平,临床效果较好。
Objective: To investigate the effect of ~ (131) I on serum sex hormones and thyroglobulin in male patients with hyperthyroidism. Methods: Totally 74 male patients with hyperthyroidism admitted to our hospital were randomly divided into control group and experimental group, with 37 patients in each group. Patients in the control group were given oral methbazol 20-30 mg daily 1 time. Patients in the experimental group were treated with ~ (131) I on the basis of the control group. After the treatment, serum free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), testosterone (T), estradiol (E2) and thyroglobulin TG) level changes and clinical efficacy. Results: Compared with those before treatment, serum levels of FT3, FT4, T, E2 and TG were significantly decreased and TSH levels were significantly increased in both groups (P <0.05). Compared with the control group, serum FT3, FT4 , T, E2, TG levels lower, TSH levels and clinical treatment of high efficiency (P <0.05). Conclusion: 131I can significantly reduce the levels of FT3, FT4, T, E2 and TG in serum and the level of TSH in male patients with hyperthyroidism. The clinical effect is good.